PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v9i6.12592ArticleLong Non-coding RNA Morrbid is Upregulated in Multiple Myeloma Patients with Type 2 Diabeteshttps://artdesignp.com/journal/PAR/9/6/10.26689/par.v9i6.12592XiangZhaoqiang,WangYaling,YanQian,ChenXiaomin,HuangChunlan2025962025-12-08Background: Long non-coding RNAs are implicated in metabolic diseases and malignancies, but their role in multiple myeloma (MM) with type 2 diabetes mellitus (T2DM) remains unclear. This study evaluated Long non-coding RNA Morrbid expression in MM patients with/without T2DM. Methods: The study enrolled 107 MM patients (48 with T2DM, 59 without) and 72 non-MM controls (23 with T2DM, 49 without). Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood samples using red blood cell lysis. Total RNA was extracted from PBMCs, followed by reverse transcription, and the expression levels of Morrbid were detected by Reverse transcription-quantitative PCR. Results: We found that the expression of Morrbid was upregulated in the MM group compared to the non-MM patients. Within the MM group, the expression of Morrbid was significantly higher in patients with T2DM than in those without T2DM. In contrast, no significant difference in Morrbid expression was observed between T2DM and non-T2DM patients in the non-MM patients. Furthermore, we discovered a positive correlation between Morrbid expression and fasting blood sugar levels in MM patients. Operating characteristic curve analysis revealed an area under the curve of 0.822 (sensitivity 77.1%, specificity 79.7%) for diagnosing T2DM in MM, suggesting that Morrbid may serve as a novel diagnostic biomarker for T2DM in MM patients. Conclusions: The high expression of Morrbid in MM patients with T2DM may indicate its critical role in tumor-related glucose metabolism. Additionally, Morrbid may potentially serve as a diagnostic biomarker for T2DM in MM patients.

Guman T, Sykora J, 2024, Impact of Autologous Stem Cell Transplantation (ASCT) on Progression Free Survival (PFS) in Newly Diagnosed Multiple Myeloma Patients (NDMM) With High Risk Cytogenetic Abnormalities. Bratislavske Lekarske Listy, 125(1): 9–11.

Katodritou E, Kastritis E, Dalampira D, et al., 2025, Evaluation of Clinical Characteristics and Prognostic Factors of Early Progressive Disease (EPD) in Newly Diagnosed Multiple Myeloma Patients: Real-World Data of the Greek Myeloma Study Group. Clinical Lymphoma, Myeloma & Leukemia, 2025: S2152-2650(25)00002-3.

Padala S, Barsouk A, Barsouk A, et al., 2021, Epidemiology, Staging, and Management of Multiple Myeloma. Medical Sciences, 9(1): 3.

Walters D, Arendt B, Jelinek D, 2013, CD147 Regulates the Expression of MCT1 and Lactate Export in Multiple Myeloma Cells. Cell Cycle, 12(19): 3175–3183.

Xue W, Li Y, Ma Y, et al., 2025, GDF15-Mediated Enhancement of the Warburg Effect Sustains Multiple Myeloma Growth via TGFβ Signaling Pathway. Cancer & Metabolism, 13(1): 3.

Zhao J, Fang Z, 2025, Single-Cell RNA Sequencing Reveals the Dysfunctional Characteristics of PBMCs in Patients With Type 2 Diabetes Mellitus. Frontiers in Immunology, 15: 1501660.

Aghaei-Zarch S, Mahmoudieh L, Miryounesi M, et al., 2025, Investigation of TNF and Related lncRNAs in Diabetic Nephropathy. Cytokine, 188: 156892.

Wang J, Li X, Geng J, et al., 2025, Identification of Biomarkers and Mechanism Exploration of Ferroptosis Related Genes Regulated by m6A in Type 2 Diabetes Mellitus. Hereditas, 162(1): 24.

Liu Y, Zou J, Xu J, et al., 2022, Comprehensive Analysis of lncRNA Expression Profile and the Potential Role of ENST00000604491 in Graves’ Disease. Journal of Immunology Research, 2022: 8067464.

Ferrer J, Dimitrova N, 2024, Transcription Regulation by Long Non-Coding RNAs: Mechanisms and Disease Relevance. Nature Reviews Molecular Cell Biology, 25(5): 396–415.

Lopez-Noriega L, Callingham R, Martinez-Sánchez A, et al., 2024, Roles for the Long Non-Coding RNA Pax6os1/PAX6-AS1 in Pancreatic Beta Cell Function. iScience, 28(1): 111518.

Xu T, Shen T, Yang S, et al., 2024, Clinical Significance of Circulating Long Non-Coding RNA SNHG1 in Type 2 Diabetes Mellitus and Its Association With Cell Proliferation of Pancreatic β-Cell. BMC Endocrine Disorders, 24(1): 225.

Wang L, Hu L, Wang X, et al., 2024, Long Non-Coding RNA LncCplx2 Regulates Glucose Homeostasis and Pancreatic β Cell Function. Molecular Metabolism, 80: 101878.

Xue W, Li Y, Ma Y, et al., 2025, GDF15-Mediated Enhancement of the Warburg Effect Sustains Multiple Myeloma Growth via TGFβ Signaling Pathway. Cancer & Metabolism, 13(1): 3.

Xiang D, Jiang L, Yuan Q, et al., 2023, Leukocyte-Specific Morrbid Promotes Leukocyte Differentiation and Atherogenesis. Research, 6: 0187.

Duarte M, Mascarenhas R, Assis A, et al., 2021, Autoimmune Regulator Act in Synergism With Thymocyte Adhesion in the Control of lncRNAs in Medullary Thymic Epithelial Cells. Molecular Immunology, 140: 127–135.

Yang H, Gao J, Zheng Z, et al., 2024, Current Insights and Future Directions of lncRNA Morrbid in Disease Pathogenesis. Heliyon, 10(17): e36681.

Smits F, Groen K, Levin M, et al., 2025, Beyond Static Measurements: Dynamic Frailty Improves Survival Prediction in Multiple Myeloma. Blood, 145(5): 543–546.

Shehnaz S, Roy A, Vijayaraghavan R, et al., 2023, Modulation of PPAR-γ, SREBP-1c and Inflammatory Mediators by Luteolin Ameliorates β-Cell Dysfunction and Renal Damage in a Rat Model of Type-2 Diabetes Mellitus. Molecular Biology Reports, 50(11): 9129–9142.

Han Z, Yan Z, Ma Z, et al., 2025, Targeting ABCD1-ACOX1-MET/IGF1R Axis Suppresses Multiple Myeloma. Leukemia, 39(3): 720–733.

Grillone K, Ascrizzi S, Cremaschi P, et al., 2024, An Unbiased lncRNA Dropout CRISPR-Cas9 Screen Reveals RP11-350G8.5 as a Novel Therapeutic Target for Multiple Myeloma. Blood, 144(16): 1705–1721.

Morelli E, Fulciniti M, Samur M, et al., 2023, A MIR17HG-Derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth. Blood, 141(4): 391–405.

Alrefai A, Khader H, Elbasuony H, et al., 2023, Evaluation of the Expression Levels of lncRNAs H19 and MEG3 in Patients With Type 2 Diabetes Mellitus. Molecular Biology Reports, 50(7): 6075–6085.

Zhang W, Zheng J, Hu X, et al., 2019, Dysregulated Expression of Long Noncoding RNAs Serves as Diagnostic Biomarkers of Type 2 Diabetes Mellitus. Endocrine, 65(3): 494–503.

Kotzin J, Spencer S, McCright S, et al., 2016, The Long Non-Coding RNA Morrbid Regulates Bim and Short-Lived Myeloid Cell Lifespan. Nature, 537(7619): 239–243.

Mello V, Kolehmanien M, Schwab U, et al., 2012, Gene Expression of Peripheral Blood Mononuclear Cells as a Tool in Dietary Intervention Studies: What Do We Know So Far?. Molecular Nutrition & Food Research, 56(7): 1160–1172.

Costa A, Stelt I, Reynés B, et al., 2023, Whole-Genome Transcriptomics of PBMC to Identify Biomarkers of Early Metabolic Risk in Apparently Healthy People With Overweight-Obesity and in Normal-Weight Subjects. Molecular Nutrition & Food Research, 67(4): e2200503.

Bai J, Xu J, Zhao J, et al., 2019, Downregulation of lncRNA AWPPH Inhibits Colon Cancer Cell Proliferation by Downregulating GLUT-1. Oncology Letters, 18(2): 2007–2012.

Mao R, Xu C, Zhang Q, et al., 2024, Predictive Significance of Glycolysis-Associated lncRNA Profiles in Colorectal Cancer Progression. BMC Medical Genomics, 17(1): 112.

Liang J, Ye C, Chen K, et al., 2023, Non-Coding RNAs in Breast Cancer: With a Focus on Glucose Metabolism Reprogramming. Discover Oncology, 14(1): 72.